College of Medical Technology,Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Department of Clinical Laboratory, People's Hospital of Deyang City, Deyang, China.
Medicine (Baltimore). 2023 Oct 20;102(42):e35361. doi: 10.1097/MD.0000000000035361.
The diagnostic efficacy of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA15-3) is limited in breast cancer (BC), highlighting the necessity of exploring novel biomarkers to improve for BC diagnosis. Therefore, we assessed the diagnostic value of fat mass and obesity-associated protein (FTO), phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit β (PIK3CB) as a potential complementary biomarker to CEA and CA153 in breast cancer by measuring serum FTO,PIK3CB levels. FTO, PIK3CB, CEA and CA15-3 levels were measured in 112 BC patients and 64 healthy controls using enzyme-linked immunosorbent assay or electrochemiluminescence immunoassay. Spearman's rank correlation analysis was conducted to assess the correlation between the levels of the 2 markers. The relationships between FTO, PIK3CB, CEA, CA15-3 and clinical characteristics were evaluated. Receiver operating characteristic curve (ROC) analysis was performed to assess the diagnostic value of FTO, PIK3CB, CEA and CA15-3 of BC. Serum FTO, PIK3CB, CEA and CA15-3 levels were significantly increased in BC. There was no correlation between FTO, PIK3CB and CEA, CA15-3. FTO and PIK3CB demonstrated significant diagnostic performance for breast cancer, with FTO achieving a specificity of 90.63%. The diagnostic performance of 2-four biomarker combinations was significantly superior to individual CEA or CA153, with a combined panel of 4 biomarkers yielding an area under the curve (AUC) of 0.918, sensitivity of 81.25% and specificity of 85.94%. In early-stage breast cancer (I + II), the combination of FTO, PIK3CB, CEA and CA153 yielded an AUC of 0.895, sensitivity of 77.22% and specificity of 85.71%. FTO and PIK3CB can be served as potential biomarkers to complement CEA and CA15-3 for BC diagnosis. Combining FTO, PIK3CB, CEA and CA15-3 improves the diagnostic efficiency of breast cancer.
癌胚抗原（CEA）和糖链抗原 15-3（CA15-3）在乳腺癌（BC）中的诊断效能有限，这突显了探索新的生物标志物以改善 BC 诊断的必要性。因此，我们通过测量血清 FTO、PIK3CB 水平，评估脂肪量和肥胖相关蛋白（FTO）、磷脂酰肌醇-4,5-二磷酸 3-激酶催化亚基β（PIK3CB）作为 CEA 和 CA15-3 的潜在互补生物标志物在乳腺癌中的诊断价值。采用酶联免疫吸附法或电化学发光免疫法检测 112 例 BC 患者和 64 例健康对照者血清 FTO、PIK3CB、CEA 和 CA15-3 水平。采用 Spearman 秩相关分析评估 2 种标志物水平之间的相关性。评估 FTO、PIK3CB、CEA、CA15-3 与临床特征之间的关系。进行受试者工作特征曲线（ROC）分析评估 FTO、PIK3CB、CEA 和 CA15-3 对 BC 的诊断价值。BC 患者血清 FTO、PIK3CB、CEA 和 CA15-3 水平显著升高。FTO、PIK3CB 与 CEA、CA15-3 之间无相关性。FTO 和 PIK3CB 对乳腺癌均具有显著的诊断性能，FTO 的特异性为 90.63%。2 种标志物联合检测对乳腺癌的诊断效能显著优于单个 CEA 或 CA153，4 种标志物联合检测的曲线下面积（AUC）为 0.918，灵敏度为 81.25%，特异性为 85.94%。在早期乳腺癌（I+II 期）中，FTO、PIK3CB、CEA 和 CA153 联合检测的 AUC 为 0.895，灵敏度为 77.22%，特异性为 85.71%。FTO 和 PIK3CB 可作为潜在的生物标志物，与 CEA 和 CA15-3 联合用于 BC 的诊断。联合检测 FTO、PIK3CB、CEA 和 CA15-3 可提高乳腺癌的诊断效率。
